June 11 (Reuters) - Kazia Therapeutics Ltd KZIA.O:
KAZIA THERAPEUTICS ANNOUNCES TRANSFORMATIVE PRECLINICAL DATA DEMONSTRATING PAXALISIB'S POTENTIAL TO OVERCOME IMMUNOTHERAPY RESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER (TNBC)
Source text: ID:nPn60mKLsa
Further company coverage: KZIA.O
((Reuters.Briefs@thomsonreuters.com;))